Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Authors

David Adams

Published

July 4, 2018

Abstract

Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin.

Supporters

Support the authors with ResearchCoin

Journal

New England Journal of Medicine

Topics

DOI

10.1056/nejmoa1716153

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Authors

David Adams

Published

July 4, 2018

Abstract

Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin.

Supporters

Support the authors with ResearchCoin

Journal

New England Journal of Medicine

Topics

DOI

10.1056/nejmoa1716153

Paper

Paper

Paper

Paper

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Abstract

Supporters

Journal

Topics

DOI

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Abstract

Supporters

Journal

Topics

DOI